|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01681 CONSUN PHARMA
Nominal 
8.620 +0.350 (+4.232%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 1,268,549 | 13.296% | 2,590,115 | 2,339,650 | 2,044,660 | 1,752,830 |
| Cost of Sales | (321,026) | 13.331% | (668,437) | (576,738) | (517,324) | (431,159) |
| Gross Profit | 947,523 | 13.284% | 1,921,678 | 1,762,912 | 1,527,336 | 1,321,671 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 433,958 | 14.924% | 863,703 | 746,393 | 695,861 | 583,736 | |
| Taxation | (32,998) | 10.825% | (77,149) | (62,696) | (108,744) | (101,993) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,195) | -- | (2,020) | (790) | 3,055 | 17,045 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 399,765 | 14.910% | 784,534 | 682,907 | 590,172 | 498,788 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (30,131) | 19.373% | (47,653) | (41,481) | (26,343) | (6,487) |
| Depreciation & Amortisation | 37,427 | -3.232% | 78,089 | 76,355 | 72,989 | 71,795 |
| Directors' Emoluments | -- | -- | 41,942 | 39,301 | 37,542 | 28,346 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 49.870 | 13.135% | 99.000 | 86.000 | 74.000 | 61.000 |
| DPS (cts) | 27.466 | -- | 40.809 | 26.265 | 24.361 | 23.449 |
| Dividend Payout Ratio (%) | 55.075% | -- | 41.221% | 30.541% | 32.920% | 38.440% |
| Cash flow per share ($) | -- | -- | 1.035 | 1.199 | 0.905 | 1.061 |
| NBV per share ($) | 4.383 | -- | 4.472 | 3.897 | 3.176 | 2.709 |
| Remarks: | Real time quote last updated: 01/11/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 399,765 |
| %Change | 14.910% |
| EPS / (LPS) | RMB 0.499 |
| NBV Per Share (¥) | RMB 4.383 |